Plus Therapeutics Appoints Desiree Smith as Corporate Controller and Principal Financial and Accounting Officer
November 08, 2019 at 06:23 am EST
Share
On November 6, 2019, the board of directors of Plus Therapeutics, Inc. approved the appointment of Desiree Smith as the Company's Corporate Controller and principal financial and accounting officer, effective immediately. Ms. Smith, age 56, joined from Outlook Amusements, Inc., where she last served as Controller from March 2018 to June 2019. Prior to joining Outlook Amusements, Inc., Ms. Smith served as Controller at XPEL Technologies, Inc. from April 2016 to July 2017.
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers. The Company combines image-guided local beta radiation and targeted drug delivery approaches. The Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). Its radiotherapeutic candidate, rhenium (186Re) obisbemeda, is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC). The Companyâs Rhenium (186Re) obisbemeda, a novel injectable radiotherapy designed to deliver targeted, high dose radiation directly into GBM tumors. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers.